Insulet

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Insulet (PODD) reports record-breaking Q4 earnings, eyes international expansion

Insulet's Q4 2022 earnings call highlighted exceptional revenue growth, strong customer adoption of Omnipod 5, and a focus on customer-centric innovation. While facing challenges with device corrections and FDA approval timelines, the company remains optimistic about revenue growth, margin improvement, and strategic investments in innovation and expansion.

Insulet reports robust Q1 growth, eyes global expansion opportunities

Insulet's Q1 2023 showcased strong financials, driven by Omnipod 5 success and U.S. market growth.
Optimism for future growth, market leadership, and expansion into underpenetrated global markets.
Challenges include declining drug delivery business and the need for continued innovation and market penetration strategies.

Insulet reports robust Q2 earnings, eyes European expansion and innovation

Insulet's Q2 performance exceeded expectations, driven by strong revenue growth and the success of Omnipod 5, showcasing the company's market strength and innovation.
While facing challenges such as inventory management and uncertainties around new products like Omnipod GO, Insulet remains optimistic about its growth trajectory and international expansion.
The company's strategic focus on consumer needs, continuous innovation, and expansion into new markets position it well for sustained leadership and revenue growth in the diabetes management sector.

Insulet excels in Q3 with Omnipod 5 driving growth

Insulet's Q3 performance was robust, driven by Omnipod 5 success.
Confidence in growth outlook, financial strength, and market positioning.
Challenges include competition, timing guidance, and market penetration.
Opportunities lie in basal market expansion and international growth potential.

Insulet (PODD) reports stellar Q4 results and eyes global expansion

Insulet's Q4 2023 performance was robust, driven by strong revenue growth and milestone achievements.
The company's strengths lie in its focus on innovation, market positioning, and strategic partnerships.
Challenges include optimizing resource allocation, reimbursement negotiations, and meeting high demand.
Opportunities for Insulet include expanding digital capabilities, driving innovation, and capturing market growth.

Insulet (PODD) reports record Q3 revenue and outlines growth strategies

Insulet's Q3 performance exceeded expectations with strong revenue and margin growth.
The company's focus on expanding Omnipod 5 platform and international growth is key.
Challenges include maintaining growth rates and sustaining pricing benefits.
Opportunities lie in accelerating international expansion and enhancing customer experience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eagle Materials

PODD stock hit new highs in March when it joined the S&P 500. Now, shares are breaking out.

New Highs: Diabetes Stock Breaks Out. Cement Maker Surges Past Buy Point.

Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.

Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up

Boston Scientific

Stryker

Zimmer Biomet Hlds

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.

4 Medical Products Stocks to Capitalize on the Industry's Recovery

Insulet Corporation (NASDAQ:PODD ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Deborah Gordon – President-Investor Relations Jim Hollingshead – President and Chief Executive Officer Wayde McMillan – Executive Vice President and Chief Financial Officer Conference Call Participants Jeff Johnson – Baird Larry Biegelsen – Wells Fargo Securities Robbie Marcus – JPMorgan Joanne Wuensch – Citibank Margaret Kaczor – William Blair Matthew O'Brien – Piper Sandler Travis Steed – Bank of America Chris Pasquale – Nephron Caitlin Cronin – Canaccord Genuity Jayson Bedford – Raymond James Matthew Taylor – Jefferies Steven Lichtman – Oppenheimer Sam Eiber – BTIG Operator Good afternoon, ladies and gentlemen, and welcome to the Insulet Corporation First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Insulet Corporation (PODD) Q1 2023 Earnings Call Transcript

Insulet (PODD) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.40 per share a year ago.

Insulet (PODD) Q1 Earnings and Revenues Top Estimates

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new organizational structure designed to accelerate innovation and commercialization. The new structure will be implemented during the second half of this year with new leadership roles effective July 1, 2023. The leadership team will continue to report to Jim Hollingshead, President and Chief E.

Insulet Announces New Organizational Structure to Drive Further Growth

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2023. First Quarter Financial Highlights: First quarter 2023 revenue of $358.1 million, up 21.2%, or 23.3% in constant currency1, compared to $295.4 million in the prior year Total Omnipod revenue of $357.6 million, an increase of 32.7%, or 34.9.

Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)

Bill.com

Booking Hlds

Americold Realty

Johnson Controls

We have narrowed our search to five stocks that are set to report earnings results this week. These are: PODD, BKNG, BILL, JCI and COLD.

Buy These 5 Stocks Ahead of Earnings Releases This Week

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets. The report details the Company's efforts to optimize value while revolutionizing health outcomes and driving a sustainable future. “As we continue to advance our missi.

Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment

Bio-Rad Laboratories

Henry Schein

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how BIO, HSIC and PODD are poised ahead of their earnings releases.

3 MedTech Stocks Likely to Beat Estimates in Q1 Earnings

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the FDA clearance of its latest innovation, Omnipod GO™, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. “Omnipod GO was designed to serve the more than three million people using basal insul.

Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes

Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Insulet (PODD) is Poised to Beat Earnings Estimates Again

Health care services and health-related stocks continue to show strength in the market. The post Option Trading: Insulet Butterfly Taps Into Stock's Leadership, Potential Rally appeared first on Investor's Business Daily.

Option Trading: Insulet Butterfly Taps Into Stock's Leadership, Potential Rally

After Insulet jumped on news it was joining the S&P 500, PODD stock is wound up for a breakout with earnings due. The post Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout With 56% Growth appeared first on Investor's Business Daily.

Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout With 56% Growth

Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.

Insulet's (PODD) New Omnipod, Strategic Moves Drive Growth

Cardinal Health

Intuitive Surgical

Vertex Pharmaceuticals

Merck

Medical stocks are holding up amid economic and market uncertainty. The post 5 S&P 500 Stocks Showing Strength As Recession Fears Rise appeared first on Investor's Business Daily.

5 S&P 500 Stocks Showing Strength As Recession Fears Rise

Insulet (PODD) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Insulet (PODD)

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2023 on May 4, 2023 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023

Insulet (PODD) witnesses continued uptake of Omnipod through the U.S. pharmacy channel.

Insulet (PODD) Benefits From Omnipod 5 Launch, Expansion

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Insulet (PODD) is a Top-Ranked Growth Stock: Should You Buy?

Insulet achieved another remarkable fiscal year, driven by the successful adoption of Omnipod 5, which is being used by growing diabetic patients globally. The management expects continued growth in its total addressable market (TAM) as it continues to improve its product portfolio.

Insulet: The Game-Changer In Diabetes Management

SVB Financial Group

S&P Indices said late Friday that Insulet Corp. PODD, -0.97% will replace Silicon Valley Bank parent SVB Financial Group SIVB, -60.41% in the S&P 500 index SPX, -1.45% at the open on Wednesday. The bank was shut down Friday by regulators.

Silicon Valley Bank out of S&P 500 index; Insulet selected to replace it

Insulet (PODD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Insulet (PODD) Upgraded to Buy: What Does It Mean for the Stock?

ACTON, Mass.--(BUSINESS WIRE)--Please replace the release issued February 23, 2023, with the following corrected version due to multiple revisions.

CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency)

Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

News for Insulet Stock (PODD)